120 related articles for article (PubMed ID: 24991314)
1. Impact of the removal of the monthly liver function test requirement for ambrisentan.
Durst LA; Carlsen J; Kuchinski M; Harner L; Neves D; Harris SJ; Traiger GL
Am Health Drug Benefits; 2012 Mar; 5(2):94-101. PubMed ID: 24991314
[TBL] [Abstract][Full Text] [Related]
2. Provision of ambrisentan from a health-system specialty pharmacy affiliated with a pulmonary hypertension Center of Comprehensive Care.
Gutenschwager DW; Patel A; Soyad AT; Patel S; Szandzik EG; Kelly B; Smith ZR
Am J Health Syst Pharm; 2024 Jan; 81(2):66-73. PubMed ID: 37611180
[TBL] [Abstract][Full Text] [Related]
3. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
Dranitsaris G; Mehta S
Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
[TBL] [Abstract][Full Text] [Related]
4. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.
McGoon MD; Frost AE; Oudiz RJ; Badesch DB; Galie N; Olschewski H; McLaughlin VV; Gerber MJ; Dufton C; Despain DJ; Rubin LJ
Chest; 2009 Jan; 135(1):122-129. PubMed ID: 18812445
[TBL] [Abstract][Full Text] [Related]
5. Ambrisentan therapy in pulmonary hypertension: clinical use and tolerability in a referral centre.
Condliffe R; Elliot CA; Hurdman J; Sabroe I; Billings C; Kiely DG; Hamilton N
Ther Adv Respir Dis; 2014 Jun; 8(3):71-77. PubMed ID: 24787237
[TBL] [Abstract][Full Text] [Related]
6. Assessment of time and practice resources required to provide weekly or monthly erythropoiesis-stimulating protein therapy to chronic kidney disease patients in the physician office setting.
Bernardo M; Crawford P; Hertel J; Sholer C; Xu X; Goss T; Kewalramani R; Globe D
J Manag Care Pharm; 2006; 12(9):714-25. PubMed ID: 17249904
[TBL] [Abstract][Full Text] [Related]
7. Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension.
Kingman M; Ruggiero R; Torres F
Expert Opin Pharmacother; 2009 Aug; 10(11):1847-58. PubMed ID: 19601701
[TBL] [Abstract][Full Text] [Related]
8. Adherence to risk evaluation and mitigation strategies (REMS) requirements for monthly testing of liver function.
Blanchette CM; Nunes AP; Lin ND; Mortimer KM; Noone J; Tangirala K; Johnston S; Gutierrez B
Drugs Context; 2015; 4():. PubMed ID: 25709706
[TBL] [Abstract][Full Text] [Related]
9. Meeting the affordability challenges posed by orphan drugs: a survey of payers, providers, and employers.
Lopata E; Terrone C; Gopalan A; Ladikos N; Richardson T
J Manag Care Spec Pharm; 2021 Jun; 27(6):706-713. PubMed ID: 33586514
[No Abstract] [Full Text] [Related]
10. Transition from Bosentan to Ambrisentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study.
Chen J; Luo J; Yang X; Luo P; Chen Y; Li Z; Li J
Int J Gen Med; 2021; 14():2101-2107. PubMed ID: 34079351
[TBL] [Abstract][Full Text] [Related]
11. Role of ambrisentan in the management of pulmonary hypertension.
Hrometz SL; Shields KM
Ann Pharmacother; 2008 Nov; 42(11):1653-9. PubMed ID: 18957622
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J
BMC Cardiovasc Disord; 2016 Oct; 16(1):201. PubMed ID: 27770771
[TBL] [Abstract][Full Text] [Related]
13. Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes.
Elshaboury SM; Anderson JR
Patient Prefer Adherence; 2013; 7():401-9. PubMed ID: 23674888
[TBL] [Abstract][Full Text] [Related]
14. US commercial health plan coverage dynamics in pulmonary arterial hypertension therapies.
Rucker JA; Beinfeld MT; Enright DE; Germack HD; Panjabi S; Chakinala MM; Chambers JD
J Manag Care Spec Pharm; 2024 Jun; 30(6):541-548. PubMed ID: 38824632
[TBL] [Abstract][Full Text] [Related]
15. A Retrospective Analysis of Adherence to Risk Evaluation and Mitigation Strategies Requirements for Pulmonary Arterial Hypertension Drugs.
Prokes M; Root A
Hosp Pharm; 2019 Oct; 54(5):309-313. PubMed ID: 31555006
[No Abstract] [Full Text] [Related]
16. Emerging trends in cancer care: health plans' and pharmacy benefit managers' perspectives on changing care models.
Greenapple R
Am Health Drug Benefits; 2012 Jul; 5(4):242-53. PubMed ID: 24991323
[TBL] [Abstract][Full Text] [Related]
17. Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study.
Vachiéry JL; Hoeper MM; Peacock AJ; Sitbon O; Cheli M; Church C; Olsson KM; Palazzini M; Waterhouse B; Langley J; Galié N
J Heart Lung Transplant; 2017 Apr; 36(4):399-406. PubMed ID: 27282418
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis.
Li M; Jing ZC; Li Y; Huo Y; Yu Z; Zhang G; Zhu P; Liu J; Ji Q; Wu B; Zhong J; Wang P; Zhu W; Zeng X
BMC Cardiovasc Disord; 2020 Jul; 20(1):339. PubMed ID: 32680480
[TBL] [Abstract][Full Text] [Related]
19. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
Kabunga P; Coghlan G
Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
[TBL] [Abstract][Full Text] [Related]
20. A review of pulmonary arterial hypertension: role of ambrisentan.
Barst RJ
Vasc Health Risk Manag; 2007; 3(1):11-22. PubMed ID: 17583171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
